Neoangiogenesis in Benign and Malignant Salivary Gland Tumors

Authors

  • Ali Bijani Social Determinant of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
  • Azadeh Gholami Department of Oral and Maxillofacial Pathology, School of Dentistry, Babol University of Medical Sciences, Babol, Iran.
  • Farzad Yazdani Department of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohammad Kashefi Dental Material Research Center, School of Dentistry, Babol University of Medical Sciences, Babol, Iran.
  • Pouyan Aminishakib Department of Oral and Maxillofacial Pathology, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.
  • Sara Mehrabi Department of Oral and Maxillofacial Pathology, School of Dentistry, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Shima Nafarzadeh Department of Oral and Maxillofacial Pathology, School of Dentistry, Babol University of Medical Sciences, Babol, Iran.
Abstract:

Introduction: There are few studies investigating the role of neoangiogenesis in biological behavior of salivary gland tumors. CD105 expression has demonstrated greater accuracy for detecting new vessel formation compared with other pan-endothelial molecules. This study aimed to assess and compare intratumoral Micro-Vessel Density (MVD) through using immunohistochemichal expression of CD105 biomarker in Mucoepidermoid Carcinoma (MEC), Adenoid Cystic Carcinoma (AdCC) and Pleomorphic Adenoma (PA). Materials and Methods: CD105 expression using Immunohistochemistry (IHC) was assessed in 20 cases of PA, 20 cases of AdCC, 20 cases of MEC, and 10 cases of normal salivary gland tissues. Positive intratumoral micro-vessels for CD105 expression were measured quantitatively for the assessment of Micro-Vessel Density (MVD) in each group. Groups differences in MVD was analyzed statistically using the Mann-Whitney U test and Kruskal-Wallis test. One-way ANOVA and post hoc Tukey test were also carried out. P values less than 0.05 were considered statistically significant. Results: CD105 positive vessels were rarely seen in normal salivary gland tissue. Statistically significant differences in MVD were observed between the normal salivary gland tissue and AdCC and also MEC (P<0.017 and P<0.001, respectively). There was a statistically significant difference in MVD between PA and AdCC and also MEC (P<0.018 and P<0.001, respectively). MVD was higher in MEC in comparison with AdCC (P<0.002). Conclusion: The results of the current study demonstrated higher neoangiogenesis in AdCC and MEC by measuring CD105 expression, which suggests a possible role for this phenomenon in aggressive behavior of these malignant salivary gland tumors.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

MTA1 Expression in Benign and Malignant Salivary gland Tumors

Introduction: Salivary gland tumors (SGTs) are important parts of human neoplasms. The most common SGT is pleomorphic adenoma and the most common malignant SGTs are mucoepidermoid carcinoma and adenoid cystic carcinoma (ACC). Metastasis-associated genes 1 (MTA1), a member of the nucleosome remodeling and histone deacetylation complex, is one newly discovered gene which recruits histone deacetyl...

full text

GSK3β and CREB3 Gene Expression Profiling in Benign and Malignant Salivary Gland Tumors

Background: Salivary gland tumors (SGT) are rare lesions with uncertain histopathology. One of the major signaling pathways that participate in the development of several tumors is protein kinase A. In this pathway, glycogen synthase kinase β (GSK3β) and cAMP responsive element binding protein (CREB3) are two genes which are supposed to be down regulated in most human tumors. The expression lev...

full text

Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors

Introduction: Cyfra 21 is a serum-soluble fragment of cytokeratin19. Increased Cyfra 21 serum levels and their benefit as a tumor marker have been shown in some malignancies. This study aimed to evaluate the serum levels of Cyfra 21 in patients with benign and malignant salivary gland tumors. Materials and Methods: In this cross-sectional study, the serum level of Cyfra 21 in 44 patients with m...

full text

mta1 expression in benign and malignant salivary gland tumors

introduction: salivary gland tumors (sgts) are important parts of human neoplasms. the most common sgt is pleomorphic adenoma and the most common malignant sgts are mucoepidermoid carcinoma and adenoid cystic carcinoma (acc). metastasis-associated genes 1 (mta1), a member of the nucleosome remodeling and histone deacetylation complex, is one newly discovered gene which recruits histone deacetyl...

full text

MTA1 Expression in Benign and Malignant Salivary gland Tumors.

INTRODUCTION Salivary gland tumors (SGTs) are important parts of human neoplasms. The most common SGT is pleomorphic adenoma and the most common malignant SGTs are mucoepidermoid carcinoma and adenoid cystic carcinoma (ACC). Metastasis-associated genes 1 (MTA1), a member of the nucleosome remodeling and histone deacetylation complex, is one newly discovered gene which recruits histone deacetyla...

full text

T-helper Type 1 and 2 Cytokine Levels in Patients with Benign and Malignant Salivary Gland Tumors

Background: Salivary gland tumors are among malignancies that have high recurrence rate. Immune responses in salivary gland tumors have not been well elucidated. T helper type 1 (Th1) and Th2 cytokines have been reported to play a role in the outcome of head and neck cancers. Objective: To evaluate the serum levels of interferon gamma (IFN- γ), as the hallmark of Th1 cytokines, and interleukin-...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 7  issue 1

pages  37- 42

publication date 2018-04

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023